Study identifier:D8224R00001
ClinicalTrials.gov identifier:NCT05645172
EudraCT identifier:N/A
CTIS identifier:N/A
Retention rate of acalabrutinib in a non-interventional setting
Chronic lymphocytic leukaemia (CLL)
Phase 4
No
-
All
200
Observational
18 Years - 99 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Cohort 1 adult CLL patients (≥ 18 years of age) newly prescribed with acalabrutinib according to clinical routine will be included independent of the patient age, disease stage, existence of genetic risk factors, comorbidities, therapy line, and of the application as combination therapy with obinutuzumab or as monotherapy. | - |